Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors ...Middle East

PR Newswire - News
Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors
SUZHOU, China, Jan. 3, 2023 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, announces that TST003,...

Hence then, the article about transcenta received ind clearance from nmpa for its first in class gremlin1 targeting antibody tst003 for the treatment of solid tumors was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Transcenta Received IND Clearance from NMPA for Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors )

Apple Storegoogle play

Last updated :

Also on site :